IOL Chemicals & Pharmaceuticals receives EDQM CEP for Clopidogrel Besilate API; stock moves up 4%IOL Chemicals & Pharmaceuticals receives EDQM CEP for Clopidogrel Besilate API; stock moves up 4%

Introduction

Leading pharmaceutical company received EDQM Certificate of Suitability for Clopidogrel Besilate, in addition to existing CEP for Clopidogrel Bisulphate, on February 23, 2026.

Also Read: Tata Steel stock on radar as new Ludhiana plant nears launch; details to know

Share price movement of IOL Chemicals

On February 25, 2026, IOL Chemicals & Pharmaceuticals Ltd opened at ₹73.85, up 2.67% from its previous close of ₹71.93. The stock reached a high of ₹74.73 (3.89%) and a low of ₹73.28. By 11:22 AM, it traded at ₹74.44, a 3.49% increase, with a market cap of ₹2,185.02 crore.

IOL Chemicals Receives CEP

IOL Chemicals and Pharmaceuticals Limited received a Certificate of Suitability from the European Directorate for the Quality of Medicines & Health Care (EDQM) for Clopidogrel Besilate on February 23, 2026.

The company already holds a valid CEP for Clopidogrel Bisulphate. Clopidogrel is an antiplatelet medication used for treatment and prevention of cardiovascular diseases.

Stock performance of IOL Chemicals for period of 1 week, 6 months, and 1 year

IOL Chemicals & Pharmaceuticals Ltd declined 3.02% over the past week and fell 20.8% over the past 6 months. The stock gained 8.01% over the past year.

Also Read: Silver Touch Technologies secures FSSAI digital overhaul mandate; here’s what it means

Shareholding pattern of IOL Chemicals

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	52.60%	52.60%	52.60%
FII	2.10%	2.30%	2.60%
DII	0%	0%	0%
Public	45%	45%	45%

About IOL Chemicals

IOL Chemicals & Pharmaceuticals Ltd (NSE: IOLCP) is a pharmaceutical APIs and specialty chemicals company, and the largest global ibuprofen manufacturer with 35% market share.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs